Etrasimod Arginine

CHEMBL3989933 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
631.7 g/mol
LogP
Phase
4

The arginine salt form of etrasimod, this sphingosine-1-phosphate receptor modulator reduces gut inflammation by preventing certain immune cells from reaching the bowel. The arginine salt supports oral bioavailability.

Peso molecular

631,7000 g/mol

TPSA

190,00 Ų

Mecanismo de acción

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N=C(N)NCCC[C@@H](N)C(=O)O.O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21

InChI

InChI=1S/C26H26F3NO3.C6H14N4O2/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-23;7-4(5(11)12)2-1-3-10-6(8)9/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t17-;4-/m11/s1

Molecular Formula

C32H40F3N5O5

HBD / HBA

6 / 10

Enlaces Rotables

11

Átomos Pesados

45

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The arginine salt form of etrasimod, this sphingosine-1-phosphate receptor modulator reduces gut inflammation by preventing certain immune cells from reaching the bowel. The arginine salt supports oral bioavailability.

Increases water content in the intestinal lumen through osmotic or stimulant mechanisms, promoting bowel motility and facilitating defecation.

Yes, Etrasimod Arginine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989933. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 44624336. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.